A Computational Insight on the Inhibitory Potential of 8-Hydroxydihydrosanguinarine (8-HDS), a Pyridone Containing Analog of Sanguinarine, against SARS CoV2**

Atala Bihari Jena+,a Namrata Kanungo+,b Gagan Bihari Nityananda Chainy,b Vinod Devaraji,c Sudipta Kumar Das,a and Jagneshwar Dandapat*+a, b

a Center of Excellence in Integrated Omics and Computational Biology, Utkal University, Bhubaneswar, 751004, Odisha, India
b Department of Biotechnology, Utkal University, Bhubaneswar, 751004, Odisha, India, e-mail: jdandapat.nou@gmail.com
c Computational Drug Design Lab, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India

The unprecedented global pandemic of COVID-19 has created a daunting scenario urging an immediate generation of therapeutic strategy. Interventions to curb the spread of viral infection primarily include setting targets against the virus. Here in this study we target S protein to obstruct the viral attachment and entry and also the M pro to prevent the viral replication. For this purpose, the interaction of S protein and M pro with phytocompounds, sanguinarine and eugenol, and their derivatives were studied using computational tools. Docking studies gave evidence that 8-hydroxydihydrosanguinarine (8-HDS), a derivative of sanguinarine, showed maximum binding affinity with both the targets. The binding energies of the ligand with S protein and M pro scored to be ΔGb = 9.4 Kcal/mol and ΔGb = 10.3 Kcal/mol, respectively. MD simulation studies depict that the phytocompound could effectively cause structural perturbations in the targets which would affect their functions. 8-Hydroxydihydrosanguinarine distorts the α-helix in the secondary structure of M pro and RBD site of S protein. Protein-protein interaction study in presence of 8-hydroxydihydrosanguinarine also corroborate the above findings which indicate that this polyphenol interferes in the coupling of S protein and ACE2. The alterations in protonation of M pro suggest that the protein structure undergoes significant structural changes at neutral pH. ADME property of 8-hydroxydihydrosanguinarine indicates this could be a potential drug. This makes the phyto-alkaloid a possible therapeutic molecule for anti COVID-19 drug design.

Keywords: sanguinarine, eugenol, 8-hydroxydihydrosanguinarine, S protein, SARS-CoV2, molecular dynamics.

Introduction

The ominous COVID-19 has gripped the globe with panic and distress. The coronavirus, also known as SARS-CoV2 because of around 79.5 % genomic identity with the RNA of SARS-CoV,[1] belongs to genus betacoronavirus.[2–4] Due to its high rate of transmission and unavailability of specific therapy; it was proclaimed as a pandemic by World Health Organization (WHO).

SARS-CoV2, the enveloped, positive sense, single stranded RNA virus, causes respiratory infections in humans.[5] The single stranded genomic RNA, ~30 kb in length,[6] comprises at least 6 open reading frames (ORFs) along with 5’ cap structure and 3’ poly A tail.[7] The first ORF occupying about two-third of the genome length encodes two translational products,
polyproteins-pp1a and -pp1ab which mediates viral replication and transcription. The viral expression is coordinated by a highly complex proteolytic processing cascade. The M pro, main protease (also known as 3 CL-pro) plays a pivotal role in processing these polyproteins into 16 mature non-structural proteins (nsps). The nsps are employed for the production of sub genomic RNAs which are required for synthesis of the structural proteins, i.e., envelope (E), spike (S), membrane (M), and nucleocapsid (N) proteins and other accessory proteins.

Various X-Ray crystallographic studies depict that M pro comprising protomers a and b consists of 306 amino acid residues. Each protomer consists of three domains, domain I (8–99 aa residues), domain II (100–183 aa residues) and domain III (200–306 aa residues). A connecting loop, between domain II and III, spans from 184 to 199 residues. The N-terminal or N finger (1–7 residues) is responsible for the proteolytic activity whereas, the C-terminal domain III of M pro plays a major role in the dimerization of protomers a and b.

The establishment of SARS-CoV in the host cell involves proteolytic processing events mediated through M pro which direct gene expression and replication. There are about 11 cleavage sites of M pro on the larger polyprotein-pp1ab with Leu-Gln Ser, Ala, Gly as recognition sequence. Thus, inhibiting this protease activity would block viral replication. Incorporation of protease inhibitors such as lopinavir/ritonavir into corona virus infected patients has responded with healthier consequences. Cure to such infections might be more improved by administration of non-covalent protease inhibitors. Most of the anti-SARS approved drugs were intended for certain other viral strains. Recently, a few clinical development programs have effectively accomplished with a coronavirus protease specific inhibitor. While clinical trials are sprinting for resolving the broad range efficiency scale of various molecules in infected patients, the main protease (M pro) seems to be a promising target in drug design.

The entry of SARS-CoV2 into host cells is mediated through the binding of glycoprotein spike protein of the virus, the S protein and host cell membrane receptor, i.e., Angiotensin Converting Enzyme 2 (ACE2). Lu et al. have suggested that receptor binding domain (RBD) of S-glycoprotein of SARS-CoV2 being similar to that of SARS-CoV, targets Angiotensin Converting Enzyme 2 (ACE2), a monomeric membrane bound receptor on human cells. Hence, it is presumed that blocking the RBD site of the spike protein would prevent viral attachment to the ACE2 receptor and entry into the host cells, thus specifying it as a target to prevent the viral infection. Though a few recent and related studies have suggested various natural products for the development/repurposing of anti SARS-CoV2 drug targeting Spike glycoprotein, Membrane glycoprotein and Main protease to the best of our knowledge none has investigated the potentiality of sanguinarine or eugenol for this purpose. The antiviral efficacy of eugenol from Syzygium aromaticum L. was documented earlier in inhibiting herpes simplex virus (HSV-1), hepatitis C virus and influenza A virus. Similarly, sanguinarine, isolated from Chelidonium majus L., displayed significant inhibition against Tobacco Mosaic Virus (TMV) and was also identified as a potential HIV protease inhibitor.

This study, therefore, takes interest in inspecting the competence of these phytocompounds, sanguinarine and eugenol and their derivatives, in preventing viral infection/replication by inhibiting M pro and blocking S protein of SARS-CoV2 through in silico approaches. Virtual screening of sanguinarine and eugenol derivatives was conducted on the basis of molecular interaction, out of them 8-hydroxydihydro-sanguinarine (8-HDS) showed the highest binding affinity. 8-HDS, a derivative of sanguinarine, obtained from Chelidonium majus L and is a benzo [c] phenanthridine type alkaloid. Sanguinarine, is known for its wide range of biological activities such as regulation of nuclear factor NF-κB, apoptosis and disintegration of microtubules. Pyridone containing analogs indeed have been proven to be potent in preventing viral replication by inhibiting certain essential viral enzymes. Also tests have been conducted for pyridone derivatives for anti-hepatitis B virus (HBV) activity and cytotoxicity in vitro. Therefore, 8-HDS containing pyridone ring (Figure S2) might prove to be effective in averting SARS-CoV2 infection.

Needless to mention that computational study minimizes biological waste, research time span and is cost-effective. In this context we have employed various computational approaches (molecular docking, simulation and ADMET) for designing of natural compound based therapeutic intervention against COVID-19. Findings of this computational study indicate the potentiality of 8-HDS as an effective and promising therapeutic agent for SARS-CoV2.
Results

Structural Analysis

The secondary structure of M protease as predicted from SOPMA (Self Optimised Prediction Method with Alignment) showed that the M protease is composed of 306 amino acid residues consisting of 89 α-helices (29.08%), 35 β-turns (11.44%), 99 random coil (32.35%) and 83 extended strands (27.12%). It was revealed through ExPASy ProtParam that there are 26 negatively charged (Asp+Glu) and 22 positively charged residues (Arg+Lys). The aliphatic index was determined as 82.12. The GRAVY (Grand Average of Hydropathicity) was found to be −0.019. The instability index was scored to be 27.65. These characteristics factually support that the protein is stable.

The estimated half-lives of M protease in mammalian reticulocytes, yeast and Escherichia coli on a comparative analysis were determined as 1.9 h, 20 h and 10 h, respectively.

Sequence Analysis

Multiple sequence alignment of M protease of SARS-CoV2 with the M protease of MERS-CoV, HCoV-NL63 and SARS-CoV was done using ClustalW. The sequence identity of M protease of SARS-CoV2 shared up to 40.52%, 47.71% and 96.07% similarity with M protease of HCoV-NL63, MERS-CoV and SARS-CoV, respectively. Thus, the results depicted that M protease of SARS-CoV2 shares maximum similarity with the M protease of SARS-CoV with only 12 mutated amino acids in comparison to SARS-CoV (Table ST3).

Structure Alignment

TM-align (https://zhanglab.ccmb.med.umich.edu/TM-align/) structures of M pro of SARS-CoV2 and SARS-CoV were superimposed for comparative analysis of structures. Due to maximum sequence similarity, these two viral strains were taken for Structure-Structure superimposition. From structural alignment studies, it was inferred that M protease of SARS-CoV2 differs from SARS-CoV in only 12 amino acids which comprises 6 mutations in Domain-I, 1 mutation in Domain-II, 4 mutations in Domain-III and 1 mutation in loop region in between Domain-II and Domain-III. Thus it was deduced from the structure alignment and sequence alignment that SARS-CoV is closely related to SARS-CoV2 (Figure 1).

Molecular Docking Analysis

The binding energies were determined as ΔGb-9.3 Kcal/mol, -8.3 Kcal/mol, -9.2 Kcal/mol, -9.4 Kcal/mol, -7.9 Kcal/mol and -9.4 Kcal/mol when S protein interacts with sanguinarine, sanguinarine analog, dihydro-sanguinarine, sanguinarinerg, sanguinarine analog 16

Figure 1. Structure-Structure alignment by superimposition of M protease of 2019-nCoV on SARS-CoV.
and 8-HDS, respectively. In contrast, $\Delta G_b$-9.8 Kcal/mol, -8.4 Kcal/mol, -9.5 Kcal/mol, -8.4 Kcal/mol, -8.3 Kcal/mol and -10.3 Kcal/mol were the energies, respectively, when M protease interacted with the above molecules. Similarly, the binding affinities scored to be $\Delta G_b$-5.5 Kcal/mol, -6.7 Kcal/mol, -5.9 Kcal/mol, -6.0 Kcal/mol, -5.9 Kcal/mol and -6.1 Kcal/mol when S protein interacts with eugenol, benzyleugenol, acetyleneugenol, eugenololeate, eugenol propionate and eugenol sulfate, respectively. In contrast, $\Delta G_b$-7.1 Kcal/mol, -8.4 Kcal/mol, -6.2 Kcal/mol, -6.4 Kcal/mol, -6.1 Kcal/mol and -6.6 Kcal/mol were the energies, respectively, when M protease interacted with the above molecules (Tables 1, ST1, ST2).

From the above data, it can be deduced that sanguinarine shows higher binding affinity towards both M pro and S protein (Table 1). Out of them 8-HDS has the highest binding affinity towards both proteins.

$S$ Protein-ACE2 Interaction in Presence of 8-HDS

The best 10 docking models with different free energies were obtained from the ClusPro web-server. The total RMSD value was taken as criteria for grouping.[31] Our study analysed 5 ClusPro docking models which were chosen based on probability of S Protein, S protein with 8-HDS to interact with the predicted binding sites of ACE2 as well as the lowest binding energy during such interactions. Average binding energy of all 5 binding positions for S Protein-ACE2 interaction is $-901.2 \text{ kJ/mol}$. Nevertheless, average binding energy for S Protein-ACE2 in presence of 8-HDS is $-771.86 \text{ kJ/mol}$ (Table 2).

Molecular Simulation Analysis

As the best docking results were observed in the case of 8-HDS with both S protein and M protease, it was taken further for molecular simulations study.

Interaction of $S$ protein with 8-HDS

The average change in displacement of atoms for all frames with respect to the reference frame in trajectory, i.e., protein ligand RMSD is stable after 40 ns which was recorded to be 2.5 Å (Figure S8) in the ‘S protein - 8-HDS’ complex. Such changes suggest that the compound, 8-HDS is capable of causing significant conformational changes in the protein during simulation. The plot illustrates, that the RMSD of ligand is smaller than that of protein, which suggests that compound has not diffused away the binding site.

The structural changes in the protein as determined through RMSF plot reveal that maximum fluctuations occur between 300–500 amino acid residues (Figure S4). It is known to us that S protein’s RBD site spans from 319 amino acids to 591 amino acid residues.[32] Therefore, it can be deduced that 8-HDS is capable of distorting the RBD site of S protein. The RMSF plot depicts peaks in the regions of $\alpha$-helices and $\beta$-sheets which otherwise show less fluctuations. Thus, the compound bears the efficacy to cause extensive conformational changes in the protein. Water bridges, H-bonds and hydrophobic interactions were involved in protein-ligand binding. Consideration of these bonds is quintessential in drug design as they influence drug specificity, metabolisation and absorption.

His1058, Ser730, and Thr778 are seen to interact with ligand over the major time course of 100 ns trajectory. The hydroxy group of pyridone ring in 8-HDS is found to be in association with the His1058 of the protein for 52 % of the 100 ns trajectory. Thr778 and Ser730 interact with the ligand though water bridges for 52 % and 33 % of the trajectory, respectively (Figure S5).

Interaction of M Protease with 8-HDS

The RMSD of the M pro - 8-HDS complex was found to be 1.25 Å (Figure 2). Though the protein ligand interaction occurs over 100 ns simulation time yet substantial interaction was observed in the first 10 ns and in between 85–100 ns.
| Protein-Ligand | Protein-Ligand 2D Interaction | Binding Affinity (Kcal/mol) | Interaction | AA: Name; AA: No |
|----------------|--------------------------------|-----------------------------|-------------|-----------------|
| M Protease-8-hydroxydihydro sanguinarine |
| Van der Waal | GLY138, SER139 |
| Carbon Hydrogen Bond | GLU288 |
| Conventional Hydrogen Bond | LYS5 |
| Unfavourable Donor Donor | GLN127 |
| Unfavourable Acceptor Acceptor | LYS5 |
| Pi-Anion | GLU290 |
| Pi-Pi Stacked | TYR126 |
| Pi-Alkyl | LYS137 |
| S Protein-8-hydroxydihydro sanguinarine |
| Van der Waal | SER596, PRO665, ILE666, GLY667 |
| Carbon Hydrogen Bond | THR768 |
| Conventional Hydrogen Bond | GLN314 |
| Pi-Cation | LYS733 |
| Pi-Sigma | ILE312, VAL772 |
| Pi-Pi T Shaped | TYR313 |
| Pi Alkyl | ILE312, PRO862, LEU 861 |
The RMSF exhibited the highest peak near the 50 amino acid residues which is an α-helix region (Figure S3). As α-helix is known to determine the functional aspects, perturbations in this region make the protein feeble in its action. Generally the fluctuations appear in the N- and C-terminal ends but peaks appearing all over the RMSF plot ensure that the compound is capable of destabilising the protein by causing conformational changes. Water bridges, H-bond and hydrophobic interactions which play a decisive role in ligand binding are persistent in this protein ligand interaction. Phe294 is observed to be involved in maximum interaction time, i.e., about 75% (Figure S7). Asp295 shows dual interaction with hydroxy group of pyridone of 8-HDS through double water bridges one for 34% and another for 30% of simulation time. Asn151 also interacts with the ligand for 40% of the simulation time (Figure 3). The information derived above from simulation study is also supported by well-aligned superimposition of 8-HDS on M Pro during 0–100 ns simulation. Amino acids Phe8, Asn151, Ile152, Asp153, Phe294, Val297, Arg298, Val303 interact with M Pro all over the simulation trajectory 0–100 ns, where 10 and 80 ns simulation trajectories show interaction of maximum 17 amino acids with 8-HDS. The minimum interactions are observed at 0 and 100 ns with 11 and 10 amino acids, respectively (Figures 4, S9 and S10).

### pKa Calculations of M Protease, S protein and its Complex with 8-HDS

Four maximum pK_a and pK_b shift values of amino acid residues of M pro and S protein in presence or absence of 8-HDS were retrieved by PROPKA2. Amino acid residues Tyr161, Tyr54, His163 and His164 showed pK_a shift values 5.5, 5.2, −4.8 and −4.8, respectively in native M pro at pH 7.0. It was observed that pK_a shift values of all four Amino acid residues changed to 5.3, 5.7, −5.8 and −4.9, respectively during interaction with 8-HDS (Figure 5, Table ST5). pK_a and pK_b shift values remain constant for S protein as well as S protein - 8-HDS complex.

### Drug Likeliness Analysis

SwissADME tool has been used to investigate the drug likeness property of the lead molecule, i.e., 8-HDS. This tool interprets the relationship between pharmacokinetic and physicochemical parameters of the lead molecule. The physicochemical properties of 8-HDS (C_{20}H_{15}NO_5) were determined, i.e., 349.3 g/mol molecular weight, 26 heavy atoms, 5 hydrogen bond acceptors, 1 hydrogen bond donor, molar refractivity

| Table 2. Protein-protein interaction depicting 5 lowest binding energies for S Protein-ACE2 complex in the presence or absence of 8-HDS. |
|---|---|---|---|
| Macromolecule | Binding Positions | Lowest Energy (kJ/mol) | Average Lowest Energy (kJ/mol) |
| S Protein-ACE2 | 1 | −923 | −901.2 |
| S Protein-ACE2 | 2 | −928.9 | |
| S Protein-ACE2 | 3 | −902.4 | |
| S Protein-ACE2 | 4 | −853.3 | |
| S Protein-ACE2 | 5 | −898.4 | |
| S protein with 8-HDS-ACE2 | 1 | −795.4 | −771.86 |
| S protein with 8-HDS-ACE2 | 2 | −786.7 | |
| S protein with 8-HDS-ACE2 | 3 | −751.4 | |
| S protein with 8-HDS-ACE2 | 4 | −766.3 | |
| S protein with 8-HDS-ACE2 | 5 | −759.5 | |

**Figure 3.** Illustration of bonds between Amino acid residues of M protease and 8-Hydroxydihydrosanguinarine during their interaction.
of 97.86, no rotatable bonds and topological polar surface area of 60.39 Å². The average lipophilicity score of iLOGP, XLOGP3, WLOGP, MLOGP and SILICOS-IT models computes to 3.03. Bioavailability score of the molecule is 0.55. It is observed that 8-HDS has moderate solubility in water. SwissADME has five different rules (Lipinski, Ghose, Veber, Egan, and Muegge) to predict drug-likeness; all 5 models render 8-HDS the competence for an effective drug molecule (Table ST4).

Discussion

In this study we have primarily analysed the molecular interactions of S protein and M protease with 8-HDS through an in silico approach. Inspecting the sequential and structural alignment through various computational tools enhances our concept for better understanding of SARS-CoV2.

Here it was inferred from sequence similarity study that M protease of SARS-CoV2 shows 96% sequential identity with that of SARS-CoV. Thus the sequence similarities confirm that SARS-CoV2 is a descendant
from SARS-CoV. Evolutionary studies state that SARS-CoV2 is more closely related to SARS-CoV which had infected several people in the year 2003 with ~10% fatality rate than MERS-CoV that had caused infection in 2012 with a fatality rate of ~36%.[33]

Because of their potential capability to fit into different environments and susceptibility to recombination and mutation, Coronaviruses can deliberately adapt to altered host range and tissue tropism.[34] The major concern now is to contain the spread of virus. Blocking the viral infection in cells through M protease inhibition and targeting the viral spike protein to prevent its attachment and entry into host cells can serve as approaches to combat against the virus. These present phytocompounds, eugenol and sanguinarine, as well as their derivatives are to be employed for the above purpose.

While the principal natural source of eugenol is clove (Syzygium aromaticum),[35] it can also be extracted from soybeans, mung beans,[36] coffee,[37] bananas[38] and herbs such as nutmeg (Myristica fragrans), cinnamon (Cinnamomum verum) and basil (Ocimum basilicum).[39] It is used in a variety of pharmaceutical products due to its antioxidant, anticarcinogenic, cytotoxic, antitumor,[35] anti-inflammatory[40] and antibacterial[41] properties. This compound was tested against viral isolates of different strains of the Herpes virus (HSV) providing protection in varying degrees.[42–44] Eugenol also exhibits antiviral properties against Herpes Simplex virus type 1 and 2, feline calicivirus, tomato yellow leaf curl virus, Influenza A virus, and four airborne phages.[45]

Extracted from the roots of Sanguinaria canadensis and other poppy-fumaria species, sanguinarine bears antitumor,[46] anti-bacterial,[47,48] antifungal[49] and anti-inflammatory properties[50] and is known to inhibit neutrophil function such as degranulation and phagocytosis in vitro.[51] This benzophenanthridine alkaloid serves as inhibitor of protein kinase C bearing structural homology with chelerythrine.[52] 8-HDS possesses a pyridone ring which bears the capacity to inhibit viral enzymes essential for its replication. Due to such antiviral properties of pyridones, they can be taken as ideal molecules for drug development.[29] Zhang et al.,[14] have also suggested that pyridone-containing inhibitors can serve for the development of effective therapeutic anti-coronaviral drugs.

The molecular docking experiments demonstrated the binding affinity of sanguinarine, eugenol and their derivatives with S protein and M protease. It was witnessed that 8-HDS showed the highest affinity with S protein and M protease with energies \( \Delta G_{b}-9.4 \) Kcal/mol and \( \Delta G_{b}-10.3 \) Kcal/mol, respectively. The binding of 8-HDS with S protein is facilitated by several bonds and interactions such as Van der Waal's (Ser596, Pro665, Ile666, Gly667); Carbon Hydrogen Bond (Thr768); Conventional Hydrogen Bonds (Lys733); Pi-Sigma (Ile312, Val772); Pi-Pi T Shaped (Tyr313); Pi-Alkyl (Ile312, Pro862, Leu861) (Figure 6, Table 2). Similarly, 'M protease - 8-HDS' complex are involved with various interactions, such as Van der Waal's interaction (Gly138, Ser139); Carbon Hydrogen Bonds (Glu288); Conventional Hydrogen Bonds (Lys5); Unfavourable Donor Donor (Gln127); Unfavourable Acceptor Acceptor (Lys5); Pi-Anion (Glu290); Pi-Pi

Figure 6. Docked pose of 8-Hydroxydihydrosanguinarine in the binding pocket of S Protein. (A) Participating amino acids in the interaction of 8-Hydroxydihydrosanguinarine and S protein by hydrogen bond, (B) Hydrogen bonds between 8-Hydroxydihydrosanguinarine and S protein in binding pocket. This Figure has been developed using Discovery Studio Visualizer (http://accelrys.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php).
Molecular Dynamics (MD) simulations were conducted to investigate the physical perturbations in the protein ligand conformation. It explores the structural and functional aspects of biological macromolecules. MD simulations exhibit flexibility of intrinsic receptors and also include treatment of water molecules rather than simple portrayal of ligand-protein interactions. Therefore, MD simulations prove to be effective in studying atomic level interactions and establishing the ligand selectivity towards the target. 8-HDS possesses the capability to fluctuate the RBD site of S protein, which interacts with ACE2 receptor of human cell for the viral infection. Structural fluctuation at RBD site may inhibit the binding of S protein and ACE2 receptor, which eventually prevent the viral infection in human cell. It was observed that during protein-protein interaction, binding energy of S Protein - ACE2 decreases in presence of the phytocompound, (i.e., 8-HDS). A significant decline of 129.34 kJ/mol in binding energy was observed during the interaction of S Protein - ACE2 in presence of 8-HDS compared to their direct binding. Therefore, it can be presumed that 8-HDS is capable of hindering the attachment of RBD site of S protein to the ACE2 receptor protein (Figures 8, 9). This would indeed pave a way for the utilisation of 8-HDS in repurposing/design of effective therapy to prevent the viral entry.

From molecular docking interaction study, it is evident that 8-HDS exhibits best binding affinity towards M protease, i.e., −10.3 kcal/mol. Molecular simulation analysis depicts that 8-HDS fluctuates the alpha helical secondary structure of M protease.

Disturbance in helix regions cause distortion of intra and inter molecular hydrogen bonding network. Such structural changes of alpha helix in M protease may cause unfolding and making it non-functional. Maximum MM-GBSA binding energy was found to be −60 Kcal/mol at 10 ns for S Protein - 8-HDS complex and lowest MM-GBSA energy was −47 Kcal/mol at 60 ns with average MM-GBSA binding energy −52.22 Kcal/mol. Similarly, for M pro - 8-HDS complex maximum MM-GBSA binding energy was −50 Kcal/mol.
mol at 80 ns and lowest was observed to be $-35$ Kcal/mol at 20 ns with average MM-GBSA binding energy $-42.54$ Kcal/mol (Figure S6).

The hydrophobic amino acids are the main dynamic force in protein folding. In general, proteins become functional after being folded into specific globular structure. During protein folding, hydrophobic amino acids get buried in the core of the protein to get protected from water, leading to the protein fold stable.$^{[53,54]}$ Phe8, Ile152, Phe294, Val297, Val303 hydrophobic Amino acids of M Pro generally interact with 8-HDS during the 100 ns simulation which caused instability in the protein (Figure S10).

In some recent studies, many natural compounds have been evaluated via molecular docking to analyse the binding affinity of these compounds with coronavirus proteins with respect to antiviral drugs. This serves as a prospective to evaluate the likelihood of these molecules as drug candidates. Sampangi-Ramaiiah et al.$^{[21]}$ have assessed binding affinities of 27 natural products towards proteases of COVID-19, out of which 15 compounds showed permissible results, i.e., they possess more binding energy than the threshold $-6.0$ kcal/mol. They also observed the highest affinities in Glabridin ($-8.0$ kcal/mol) and Gluco-brassin ($-8.1$ kcal/mol) which were reasonable to compare with Sanquinavir ($-9.2$ kcal/mol), the synthetic antiviral drug, as a positive control. Similarly, Suravajhala et al.$^{[22]}$ have conducted molecular docking of 14 drug candidates with SARS-CoV2 protein in which curcumin showed good binding affinity with nucleocapsid ($-8.75$ kcal/mol) and nsp10 ($-7.85$ kcal/mol), compared to ivermectin, azithromycin and remedesivir.

Meanwhile, in our present study, the anticipating drug molecule, 8-HDS shows even greater binding affinities towards the S protein ($-9.4$ kcal/mol) and M pro ($-10.3$ kcal/mol). This definitely renders the molecule more likelihood to be accepted as an anti-covid drug.

Molecular simulation analysis corroborates docking studies revealing that 8-HDS can efficiently destabilise the S protein and M protease thereby inhibiting their functions. In a more recent study, Zhang et al.$^{[14]}$ has opined that pyridone containing ligand can potentially improve the half-life of the compound in plasma thus development of the pyridone containing inhibitor would play an important role towards the development of anti-coronaviral drug. It is therefore quite reasonable that the pyridone containing sanguinarine
For a molecule to be an effective drug, it needs to reach the target in optimised concentration and be available in bioactive form till the necessary biological events occur. The SwissADME technology makes the process of drug discovery with less time and resource consuming. Appraisal of the structural or physicochemical properties of development compounds for drug-likeness is enough to consider it as an oral drug candidate.\textsuperscript{[55]} Drug-likeness of a molecule is evaluated with respect to bioavailability by qualitatively examining the probability of the molecule to be developed into an oral drug.

The pink core area of bioavailability radar representing lipophilicity, size, polarity, solubility, saturation and flexibility define the optimal range of properties for drug-likeness of the input molecule, 8-HDS (Figure 10, Table ST4). Due to zero rotatable bonds 8-HDS have no Bioavailability Radar in the flexibility region. The BOILED-Egg model\textsuperscript{[56]} predicts easy penetration of 8-HDS through blood-brain barrier (BBB) and human gastrointestinal absorption (HIA). From the Physicochemical, Lipophilicity, Water Solubility, Pharmacokinetics, Drug-likeness properties of 8-HDS, the study arrives at a conclusion that 8-HDS could be a potential drug. The resulting changes in protonation of M pro are in good agreement that the protein structure undergoes significant structural changes at neutral pH.\textsuperscript{[57]} Our study primarily focuses on 8-HDS which can be a promising drug molecule against SARS-CoV2 due to the presence of a pyridone ring. This phytocompound is known for its antiviral properties and shows

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{bioavailability_radar.png}
\caption{The Bioavailability Radar depicts glimpse of the drug-likeness of a molecule. The pink area represents the optimal range for each properties of 8-hydroxydihydrosanguinarine.}
\end{figure}
drug likeness, structural alteration, binding affinity and molecular interaction. These findings infer that 8-HDS could serve as an effective and potential drug molecule.

Conclusion

The COVID-19 pandemic has become a global consternation by infecting millions of people worldwide, claiming several thousand lives and having shaken the socio-economic stability. It calls for an urge to stop the march of rapidly dwindling scourge. Our research via computational tools establishes that 8-hydroxydihydrosanguinarine can be an efficient inhibitor in blocking viral infection. Thus it can prove to be a potential molecule in therapeutic drug development against COVID-19.

Experimental Section

Sequence Analysis

Using PDB database, the cryo EM structure of COVID-19 S protein (PDB ID - 6vsb) and X-Ray diffraction structure of COVID-19M pro (PDB ID - 6y84) having resolution 3.46 Å and 1.39 Å, respectively have been obtained for computational study. For analysing multiple sequence alignment the FASTA sequences of M protein of 2019-nCoV, MERS-CoV, HCoV-NL63, SARS-CoV were also derived. FASTA sequence of M pro of above PDB structure was taken for the analysis of its physicochemical property and secondary structure prediction in ExPASy ProtParam and SOPMA tools, respectively.

Molecular Docking Analysis between M pro and S protein with Sanguinarine and Eugenol and their Derivatives

The binding affinities of M pro and S protein with different derivatives of sanguinarine and eugenol were evaluated through molecular docking program AutoDock Tools 1.5.6. The canonical SMILES ids of sanguinarine and eugenol along with their derivatives were acquired from PubChem database (https://pubchem.ncbi.nlm.nih.gov/). CHIMERA 1.11.2[58] programme was used for the conversion of 3D structures. Binding affinity of M pro and S protein with derivatives of sanguinarine and eugenol was estimated using AutoDock Vina 1.1.2.[59] Various parameters such as binding affinity, receptors interacting atom, receptor pocket atom, receptor ligand interaction site, atomic contact energy (ACE) and side amino acid residues were studied to recognise the binding site of M pro. Virtual screening of sanguinarine and eugenol derivatives was conducted on the basis of molecular interaction. The grid box was constructed using 108, 111, and 126, pointing in x, y, and z directions, respectively, with a grid point spacing of 0.508 Å. The center grid box is of 226.424 Å, 246.133 Å and 255.205 Å around the selected amino acids were based on the RBD site of S protein. Similarly, for M protein grid box was 62, 80, 86 pointing in x, y, and z directions, respectively with center grid box is of 11.639 Å, 0.822 Å, 4.565 Å around the selected amino acids were based on the CASTp result for M protein. The given parameters were same for both compounds during molecular interaction study. Pictorial depiction of docking results were analysed by Discovery Studio 2017 R2 Client.[60]

S Protein-ACE2 Interaction in Presence of 8-HDS

A computerised rigid body docking tool, clusPro 2.0 was used for S protein ACE2 protein docking analysis in presence or absence of 8-HDS. This tool helps in screening docked conformations with respect to their clustering properties taking into consideration different protein parameters. The selection of the filtered conformations was based on the assessment of empirical free energy. Both lowest de-solvation and electrostatic energies were taken into account for the evaluation of free energy. ClusPro is accessible at https://cluspro.bu.edu/publications.php. Piper, being a FFT-based rigid docking tool, serves the ClusPro clustering program for detecting native site by providing 1000 low energy outcomes.[61] The native site is assumed to possess a wide range of free-energies to draw greater number of results. Initially the sample was taken for about 10^9 positions of the ligand with respect to the receptor. Out of these, only the top 10^3 positions were selected among all relative ligand positions in correspondence to the receptor.

Molecular Simulation

The ligand 8-HDS was extracted in chemically unstandardized 2D structures from PubChem database (https://pubchem.ncbi.nlm.nih.gov/). LigPrep[62] was used to standardise the ligand files, lower energy and extrapolated 3D structures which were virtually screened by Glide.[63] The ‘M protein - 8-HDS’ and ‘S protein - 8-HDS’ complex was formed using Grid-based Ligand Docking with Energetics (GLIDE) module of Schrodinger software. Molecular dynamics simula-
tions were determined using Desmond\textsuperscript{[64]} software. Root Mean Square Deviations (RMSD) and atomic fluctuation were studied through RMSF. Different simulation boxes and tools such as cubic, orthorhombic, truncated octahedron and rhombic dodecahedron were taken up for precisely directing solvent simulations with periodic marginal conditions. An 8-staged stabilization run was conducted prior to 100 ns production run. Beginning primarily with task, then followed by simulations with NVT at $T = 10$ K and small time steps in Brownian Dynamics and restraints on solute heavy atoms for 100 ps. The third stage included repetition of the above stage but with restraints on solute heavy atoms for 12 ps, the following 4th stage was also carried out in a similar manner with NPT instead of NVT. In stage 5, solvate pockets were focussed. Similar to stage 4, the stage 6 was carried out. The next stage was concerned with simulation at NPT for 24 ps with no restraints. Ultimately, simulations were done.

In this study, molecular simulations were performed specifically for the top two identified hits to study the stability of the ligand receptor complex for 100 ns. Stability of docked complexes of ‘S protein - 8-HDS’ and ‘M pro - 8-HDS’ till 100 ns simulation time was checked using system builder of Desmond implemented in Maestro.\textsuperscript{[65]} The system for ‘S Protein - 8-HDS’ and ‘M pro - 8-HDS’ were immersed in a water filled cubic box of 10 Å spacing containing 64002 and 10297 water molecules, respectively, with system builder of the Desmond in the Maestro program using extended simple point charge (SPC). Neutralisation of the docked complex was done by the addition of 2 Na\textsuperscript{+} ions (3.531 mM concentration) with +2 charges into the system for M pro and 8-HDS. Similarly, for S protein and 8-HDS neutralization of docked complex was done by addition of 4 Na\textsuperscript{+} ions (1.136 mM concentration) with +4 charges into the system.

Molecular Mechanics Generalized Born Surface Area (MM-GBSA) method has been followed for the calculation of binding free energies of 8-HDS with S protein and M pro, respectively. The more negative value indicates stronger binding as the MM-GBSA in an index of free energy of binding. Prime module\textsuperscript{[66]} was used to calculate MM-GBSA binding free energy under equilibrated trajectory of molecular dynamics. The potential energy was seen to decline in the case of both ‘M pro - 8-HDS’, ‘S protein - 8-HDS’ complexes during the 100 ns which revealed that the system is stable. The different conformations formed over 100 ns simulation period were analysed. The average change in the displacement of selected atoms in a particular frame with respect to reference frame was computed by estimation of RMSD of protein and ligand over simulation trajectory for 100 ns.

\textbf{pKa Calculations}

PROPKA program is one of the widely used approaches for calculating of pKa values in proteins. PROPKA generates convenient structural rationalization of the predicted pKa values. In this program, Graphical User Interface (GUI) tool was employed for computing the pH-dependent properties of proteins such as charge and stabilization energy by providing a direct link between the structure and the pKa data (predicted by the PROPKA calculation, via the Visual Molecular Dynamics (VMD) program).\textsuperscript{[67]} PROPKA 2.0 was used to calculate the pKa value of M protease, S protein and protein ligand complex ‘S protein - 8-HDS’ and ‘M protease-8-HDS’ at pH 7.0.

\textbf{Drug Likeliness Analysis}

Swiss ADME is a robust web tool to access physicochemical properties, pharmacokinetics, drug-likeliness and medical chemistry friendliness of a molecule to determine its proficiency to be used as a drug. Bioavailability Radar (lipophilicity, size, polarity, solubility, saturation and flexibility) has been used for this purpose to calculate drug-likeness. Assessment of ADME (absorption, distribution, metabolism and excretion) is essential for drug design. The Canonical SMILES of 8-HDS was retrieved from PubChem database and the ADME properties were predicted at Swiss ADME (http://www.swissadme.ch/).

\textbf{Abbreviations}

8-HDS: 8-Hydroxydihydrosanguinarine;
ACE: Atomic contact energy;
ACE2: Angiotensin Converting Enzyme 2;
ADME: Absorption, Distribution, Metabolism and Excretion;
BBB: Blood-brain barrier;
COVID-19: CoronaVirus Disease 2019;
GLIDE: Grid-based Ligand Docking with Energetics;
GUI: Graphical User Interface;
HBV: Anti-hepatitis B virus;
HIA: Human gastrointestinal absorption;
Author Contribution Statement

A.B.J., J.D. and G.B.N.C. conceptualised and designed the experiment. A.B.J. and N.K. made the computational study. V.D. and S.K.D. made the data analysis. All the authors contributed in writing and editing of the manuscript.

References

[1] F. A. Rabi, M. S. Al Zoubi, G. A. Kasasbeh, D. M. Salameh, A. D. Al-Nasser, ‘SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far’, Pathogens 2020, 9, 231.

[2] P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, ‘A pneumonia outbreak associated with a new coronavirus of probable bat origin’, Nature 2020, 579, 270 – 273.

[3] C. Wu, Y. Liu, Y. Yang, P. Zhang, W. Zhong, Y. Wang, Q. Wang, Y. Xu, M. Li, X. Li, M. Zheng, L. Chen, H. Li, ‘Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods’, Acta Pharm. Sin. 8 2020, 10, 766 – 788.

[4] S. Dong, J. Sun, Z. Mao, L. Wang, Y.-L. Lu, J. Li, ‘A guideline for homology modeling of the proteins from newly discovered betacoviruses, 2019 novel coronavirus (2019-nCoV)’, J. Med. Virol. 2020, 92, 1542 – 1548.

[5] S. F. Ahmed, A. A. Quadeer, M. R. McKay, ‘Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies’, Viruses 2020, 12, 254.

[6] R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W. J. Liu, D. Wang, W. Xu, E. C. Holmes, G. F. Gao, G. Wu, W. Chen, W. Shi, W. Tan, ‘Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding’, Lancet 2020, 395, 565 – 574.

[7] M. U. Mirza, M. Froeyen, ‘Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase’, J. Pharm. Anal. 2020, 10, 320 – 328.

[8] W. Dai, B. Zhang, X.-M. Jiang, H. Su, J. Li, Y. Zhao, X. Xie, Z. Jin, J. Peng, F. Liu, C. Li, Y. Li, F. Bai, H. Wang, X. Cheng, X. Cen, S. Hu, X. Yang, J. Wang, X. Liu, G. Xiao, H. Jiang, Z. Rao, L.-K. Zhang, Y. Xu, H. Yang, H. Liu, ‘Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease’, Science 2020, 368, 1331 – 1335.

[9] A. R. Fehr, S. Perlman, in Coronaviruses: Methods in Molecular Biology, Eds. H. Maier, E. Hickerton, P. Britton, Humana Press, New York, 2015, Vol. 1282, p. 1.

[10] M. Prajapat, P. Sarma, N. Shekhark, A. Prakash, P. Avti, A. Bhattacharyya, H. Kaur, S. Kumar, S. Bansal, A. R. Sharma, B. Medhi, ‘Update on the target structures of SARS-CoV-2: A systematic review’, Indian J. Pharmacol. 2020, 52, 142 – 149.

[11] X. Xue, H. Yu, H. Yang, F. Xue, Z. Wu, W. Shen, J. Li, Z. Zhou, Y. Ding, Q. Zhao, X. C. Zhang, M. Liao, M. Bartlam, Z. Rao, ‘Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design’, J. Virol. 2008, 82, 2515 – 2527.

[12] K. Anand, G. J. Palm, J. R. Mesters, S. G. Siddell, J. Ziebuhr, R. Hilgenfeld, ‘Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain’, EMBO J. 2002, 21, 3213 – 3224.
[13] J. Shi, Z. Wei, J. Song, 'Dissection study on the severe acute respiratory syndrome 3 C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors', J. Biol. Chem. 2004, 279, 24765–24773.

[14] L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, 'Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors', Science 2020, 368, 409–412.

[15] A. Zumla, J. F. W. Chan, E. I. Azhar, D. S. C. Hui, K.-Y. Yuen, 'Coronaviruses - drug discovery and therapeutic options', Nat. Rev. Drug Discovery 2016, 15, 327–347.

[16] A.-T. Ton, F. Gentile, M. Hsing, F. Ban, A. Cherkasov, 'Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 Billion compounds', Mol. Integ. 2020, 39, e2000028.

[17] I.-L. Lu, N. Mahindroo, P.-H. Liang, Y.-H. Peng, C.-J. Kuo, K.-C. Tsai, H.-P. Hsieh, Y.-S. Chao, S.-Y. Wu, 'Structure-based drug design and structural biology study of novel non-peptide inhibitors of severe acute respiratory syndrome coronavirus main protease', J. Med. Chem. 2006, 49, 5154–5161.

[18] J. E. Blanchard, N. H. Elowe, C. Huitema, P. D. Fortin, J. D. Cecchetto, L. D. Ellis, E. D. Brown, 'High-throughput screening identifies inhibitors of the SARS coronavirus main protease', Chem. Biol. 2004, 11, 1445–1453.

[19] A. B. Jena, N. Kanungo, V. Nayak, G. B. N. Chainy, J. Dandapat, 'Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies', Sci. Rep. 2021, 11, 2043.

[20] J. F. Riordan, 'Angiotensin-I-converting enzyme and its relatives', Genome Biol. 2003, 4, 225.

[21] M. H. Sampanji-Ramaiah, 'Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease', Curr. Sci. 2020, 118, 1087–1092.

[22] R. Suravajhala, A. Parashar, B. Malik, V. A. Nagaraj, G. Padmanaban, P. B. K. Kishor, R. Polavarapu, P. Suravajhala, 'Comparative Docking Studies on Curcumin with COVID-19 Proteins', Preprints 2020.

[23] Y. Tragoolpua, A. Jatisatien, 'Anti-herpes simplex virus activities of Eugenia Caryophyllus (Spreng.) Bullock & S. G. Harrison and essential oil, eugenol', Phytother. Res. 2007, 21, 1153–1158.

[24] M. Ulanowska, B. Olas, 'Biological properties and prospects for the application of Eugenol – a review', Int. J. Mol. Sci. 2021, 22, 3671.

[25] W. Guo, X. Lu, B. Liu, H. Yan, J. Feng, 'Anti-TMV activity and mode of action of three alkaloids isolated from Chelidonium majus', Pest Manage. Sci. 2021, 77, 510–517.

[26] T.-J. Cheng, D. S. Goodsell, C.-C. Kan, 'Identification of Sanguinarine as a novel HIV protease inhibitor from high throughput screening of 2000 drugs and natural products with a cell-based assay', Lett. Drug Des. Discovery 2005, 2, 364–371.

[27] K.-M. Cho, I.-D. Yoo, W.-G. Kim, '8-hydroxydihydrochelerythrine and 8-hydroxydihydrosanguinarine with a potent acetycholinesterase inhibitory activity from Chelidonium majus L.', Biol. Pharm. Bull. 2006, 29, 2317–2320.

[28] I. Mackraj, T. Govender, P. Gathiram, 'Sanguinarine', Cardiovasc. Drug Rev. 2008, 26, 75–83.

[29] P. S. Dravovich, T. J. Prins, R. Zhou, T. O. Johnson, Y. Hua, H. T. Luu, S. K. Sakata, E. L. Brown, F. C. Maldonado, T. Tuntland, C. A. Lee, S. A. Fuhrman, L. S. Zalman, A. K. Patick, D. A. Matthews, E. Y. Wu, M. Guo, B. C. Borer, N. K. Nayyar, T. Moran, L. Chen, P. A. Rejto, P. W. Rose, M. C. Guzman, E. Z. Dovalsantos, S. Lee, K. McGee, M. Mohajeri, A. Liese, J. Tao, M. B. Kosa, B. Liu, M. R. Batugo, J.-P. R. Gleeson, Z. P. Wu, J. Liu, J. W. Meador, R. A. Ferre, 'Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics', J. Med. Chem. 2003, 46, 4572–4585.

[30] Z. Lv, C. Sheng, T. Wang, Y. Zhang, J. Liu, J. Feng, H. Sun, H. Zhong, C. Niu, K. Li, 'Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives', J. Med. Chem. 2010, 53, 660–668.

[31] M. Pi, K. Kapoor, R. Ye, S. K. Nishimoto, J. C. Smith, J. Baudry, L. D. Quarles, 'Evidence for Osteocalcin Binding and Activation of GPRC6 A in β-Cells', Endocrinology 2016, 157, 1866–1880.

[32] D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, 'Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation', Science 2020, 367, 1260–1263.

[33] A. Bleibtreu, M. Bertine, C. Bertin, N. Houhoud-Fidouh, B. Visseaux, 'Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)', Med. Mal. Infect. 2020, 50, 243–251.

[34] R. L. Graham, R. S. Baric, 'Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission', J. Virol. 2020, 84, 3134–3146.

[35] D. P. Bezerra, G. C. G. Militão, M. C. De Morais, D. P. De Sousa, 'The Dual Antioxidant/Prooxidant Effect of Eugenol and Its Action in Cancer Development and Treatment', Nutrients 2017, 9, 1367.

[36] K. G. Lee, T. Shimamoto, 'Antioxidant properties of aroma compounds isolated from soybeans and mung beans', J. Agric. Food Chem. 2000, 48, 4290–4293.

[37] G. Charalambous, G. Inglett (Eds), 'The Quality of Foods and Beverages: Chemistry and Technology', Academic Press, New York, Volume 2, 1981.

[38] M. J. Jordán, K. Tandon, P. E. Shaw, K. L. Goodner, 'Aromatic profile of aqueous banana essence and banana fruit by gas chromatography-mass spectrometry (GC/MS) and gas chromatography-oilfactometry (GC–O)', J. Agric. Food Chem. 2001, 49, 4813–4817.

[39] G. P. Kamatou, I. Vermaak, A. M. Viljoen, 'Eugenol from the remote Maluku Islands to the international market place: a review of a remarkable and versatile molecule', Molecules 2012, 17, 6953–6981.

[40] A. Marchese, R. Barbieri, E. Coppo, I. E. Orhan, M. Daglia, S. F. Nabavi, M. Izadi, M. Abdollahi, S. M. Nabavi, M. Ajami, 'Antimicrobial activity of eugenol and essential oils containing eugenol: A mechanistic viewpoint', Crit. Rev. Microbiol. 2017, 43, 668–689.

[41] F. Chen, Z. Shi, K. G. Neoh, E. T. Kang, 'Antioxidant and antibacterial activities of eugenol and carvacrol-grafted chitosan nanoparticles', Biotechnol. Bioeng. 2009, 104, 30–39.
[42] Y. Tragoolpua, A. Jatisatienr, ‘Anti-herpes simplex virus activities of Eugenia caryophyllus (Spreng.) Bullock & S. G. Harrison and essential oil, eugenol’, Phytother. Res. 2007, 21, 1153–1158.

[43] F. Benencia, M. C. Courrèges, ‘In vitro and in vivo activity of eugenol on human herpesvirus’, Phytother. Res. 2000, 14, 495–500.

[44] J. Serkedjieva, S. Ivancheva, ‘Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L’, J. Ethnopharmacol. 1998, 64, 59–68.

[45] T. Lane, M. Anantpadma, J. S. Freundlich, R. A. Davey, P. B. Madrid, S. Ekins, ‘The Natural Product Eugenol Is an Inhibitor of the Ebola Virus in vitro’, Pharm. Res. 2019, 36, 104.

[46] M. Wink, ‘Allelochemical properties or the Raison D’être of Alkaloids’, Alkaloids Chem. Pharmacol. 1993, 43, 1–118.

[47] G. Y. Zuo, F. Y. Meng, X.Y. Hao, Y.L. Zhang, G.C. Wang, G.L. Xu, ‘Antibacterial alkaloids from Chelidonium majus Linn (papaveraceae) against clinical isolates of methicillin-resistant Staphylococcus aureus’, J. Pharm. Pharmacol. 2008, 11, 90–94.

[48] G. Y. Zuo, F. Y. Meng, J. Han, X.-Y. Hao, G.-C. Wang, Y.-L. Zhang, Q. Zhang, ‘In vitro activity of plant extracts and alkaloids against clinical isolates of extended-spectrum β-lactamase (ESBL)-producing strains’, Molecules 2011, 16, 5453–5459.

[49] F. Meng, G. Zuo, X. Hao, G. Wang, H. Xiao, J. Zhang, G. Xu, ‘Antifungal activity of the benzophenanthridine alkaloids from Chelidonium majus Linn against resistant clinical yeast isolates’, J. Ethnopharmacol. 2009, 125, 494–496.

[50] J. Lenfeld, M. Kroutil, E. Marsálek, J. Slavík, V. Preininger, V. Šimánek, ‘Antiinflammatory activity of quaternary benzophenanthridine alkaloids from Chelidonium majus’, Planta Med. 1981, 43, 161–165.

[51] S. Agarwal, M. A. Reynolds, S. Pou, D. E. Peterson, J. A. Charon, J. B. Suzuki, ‘The effect of sanguinarine on human peripheral blood neutrophil viability and functions’, Oral Microbiol. Immunol. 1991, 6, 51–61.

[52] J. M. Herbert, J. M. Augereau, J. Gleye, J. P. Maffrand, ‘Chelerythrine is a potent and specific inhibitor of protein kinase C’, Biochem. Biophys. Res. Commun. 1990, 172, 993–999.

[53] A. B. Jena, R. R. Samal, K. Kumari, J. Pradhan, G. B. N. Chainy, U. Subudhi, S. Pal, J. Dandapat, ‘The benzene metabolite p-benzoquinone inhibits the catalytic activity of bovine liver catalase: A biophysical study’, Int. J. Biol. Macromol. 2021, 167, 871–880.

[54] E. van Dijk, A. Hoogeveen, S. Abeln, ‘The hydrophobic temperature dependence of amino acids directly calculated from protein structures’, PLoS Comput. Biol. 2015, 11, e1004277.

[55] A. Daina, O. Michielin, V. Zoete, ‘SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules’, Sci. Rep. 2017, 7, 42717.

[56] A. Daina, V. Zoete, ‘A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules’, ChemMedChem 2016, 11, 1117–1121.

[57] D. C. Bas, D. M. Rogers, J. H. Jensen, ‘Very fast prediction and rationalization of pKa values for protein-ligand complexes’, Proteins 2008, 73, 765–783.

[58] E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, ‘UCSF Chimera, a visualization system for exploratory research and analysis’, J. Comput. Chem. 2004, 25, 1605–1612.

[59] O. Trott, A. J. Olson, ‘AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading’, J. Comput. Chem. 2010, 31, 455–461.

[60] Dassault Systèmes BIOVIA, ‘BIOVIA Discovery Studio – BIOVIA – Dassault Systèmes’, https://www.3ds.com/products-services/biovia/products/molecular-modeling-simulation/biovia-discovery-studio/, 2017, Accessed on September 29, 2021.

[61] D. Kozakov, D. R. Hall, B. Xia, K. A. Porter, D. Padhoryn, C. Yueh, D. Beglov, S. Vajda, ‘The ClusPro web server for protein-protein docking’, Nat. Protoc. 2017, 12, 255–278.

[62] Schrödinger Release 2020-2, ‘Announcing Schrödinger Software Release 2020-2, Schrödinger’, https://www.schrodinger.com/user-announcement/announcing-schrodinger-software-release-2020-2, 2020, Accessed on September 29, 2021.

[63] R. A. Friesner, R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin, D. T. Mainz, ‘Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes’, J. Med. Chem. 2006, 49, 6177–6196.

[64] Schrödinger Release 2020-2: Desmond Molecular Dynamics System (2020), D. E. Shaw Research, New York, NY. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY. Accessed on September 29, 2021.

[65] Schrodinger Release 2020-2, ‘Maestro (2020) Maestro | Schrödinger’, https://www.schrodinger.com/products/maestro. Accessed on September 29, 2021.

[66] Schrodinger Release 2018-2: Prime, Schrodinger. Schrodinger, LLC, New York, NY. Accessed on September 29, 2021.

[67] M. Rostkowski, M. H. Olsson, C. R. Søndergaard, J. H. Jensen, ‘Graphical analysis of pH-dependent properties of proteins predicted using PROPKA’, BMC Struct. Biol. 2011, 11, 6.